Log in to search using one of your social media accounts:


Thirty-Day Outcomes in 100 Consecutive Patients Undergoing Transfemoral Aortic Valve Replacement With the Portico Valve on an All-Comer Basis.

Thirty-Day Outcomes in 100 Consecutive Patients Undergoing Transfemoral Aortic Valve Replacement With the Portico Valve on an All-Comer Basis. J Invasive Cardiol. 2017 Dec;29(12):431-436 Authors: Mas-Peiro S, Vasa-Nicotera M, Weiler H, Papadopoulos N, De Rosa R, Zeiher AM, Fichtlscherer S Abstract OBJECTIVES: Transcatheter heart valves such as the self-expandable Portico valve (St. Jude Medical) are being developed to overcome limitations of first-generation devices. Since clinical experience with this valve is still limited in a real-world setting, we investigated its use on an all-comer basis. METHODS: Between October 2015 and October 2016, a total of 100 consecutive patients assessed for transcatheter aortic valve replacement (TAVR) and found suitable for the Portico valve were included. The primary endpoint was 30-day all-cause mortality. Secondary endpoints included immediate postprocedural survival, complications according to Valve Academic Research Consortium (VARC)-2 criteria, and echocardiographic findings. RESULTS: All 100 participants received a Portico valve; the patient group included 56 women (56%) and 44 men (44%) with mean age of 81.7 ± 5.1 years. Mean EuroScore II and STS scores were 6.2 ± 8.6 and 5.2 ± 6.1, respectively. Immediate postprocedural survival rate was 99%. The 30-day mortality rate (6%) was comparable with earlier studies performed in selected patients. Complications included major stroke (2%), mi...
Source: The Journal of Invasive Cardiology - Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Related Links:

Time limit: 0 Quiz-summary 0 of 20 questions completed Questions: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Information This test series requires login for attempting. You can login easily with your Facebook account (Use the CONNECT WITH icon on the upper part of right sidebar displaying t...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: General Cardiology Source Type: blogs
Background— Surgical aortic valve replacement in patients with small annular dimensions is challenging because they are at increased risk for prosthesis–patient mismatch and impaired outcomes. Transcatheter aortic valve replacement might be a good alternative; however, comparative data on different transcatheter heart valves are missing. Methods and Results— This multicenter, propensity score–matched study compared hemodynamics and early clinical outcomes in 246 patients with an aortic annulus area
Source: Circulation: Cardiovascular Interventions - Category: Cardiology Authors: Tags: Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Structural Heart Disease Source Type: research
ConclusionObjective calculation of both the benefit and risks of anticoagulation in the postā€operative patient is significantly altered by including the effect on patient's quality of life utility value. Therapeutic anticoagulation in some common situations is probable to be of more detriment than benefit when considering health utility.
Source: ANZ Journal of Surgery - Category: Surgery Authors: Tags: Original Article Source Type: research
Boston Scientific (NYSE:BSX) said its Lotus replacement heart valve beat the competing CoreValve device made by Medtronic (NYSE:MDT) in a head-to-head trial. Data from the Reprise III study, billed as the 1st head-to-head pivotal trial comparing transcatheter aortic valve replacements, were released today at the annual EuroPCR meeting in Paris. The 912-patient study compared Lotus with the CoreValve and CoreValve Evolut devices in high- and extreme-risk patients. The primary efficacy endpoint was the composite rate of death, disabling stroke and moderate or greater paravalvular leakage at 1 year; the primary...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Replacement Heart Valves Wall Street Beat Boston Scientific Edwards Lifesciences europcr2017 Medtronic Source Type: news
ConclusionsAVR using On-X valve with low target INR regimen and low-dose aspirin resulted in a significantly low risk of bleeding.
Source: General Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
CONCLUSIONS: -Results from the SOURCE 3 Registry demonstrate contemporary European trends and good outcomes of TAVI in daily practice when using this third generation TAVI device. PMID: 28104716 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Authors: Steffen J, Köhler A, Schwarz F, Sadoni S, Hagl C, Massberg S, Greif M Abstract Transcatheter aortic valve replacement (TAVR) is used for the treatment of aortic stenosis (AS). Besides major bleeding, conduction blocks, stroke or atrial fibrillation, complications include cardiac perforation with possible left-to-right-shunts. Herein is reported the sixth case of a left-to-right shunt in an 87-year-old man who underwent TAVR using a 29 mm Edwards SAPIEN S3 prosthesis to treat AS. Soon after the procedure, a small channel evolving from the right coronary cusp could be detected on echocardiography. The p...
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
Authors: Onorati F, D'Onofrio A, Biancari F, Salizzoni S, De Feo M, Agrifoglio M, Mariscalco G, Lucchetti V, Messina A, Musumeci F, Santarpino G, Esposito G, Santini F, Magagna P, Beghi C, Aiello M, Della Ratta E, Savini C, Troise G, Cassese M, Fischlein T, Glauber M, Passerone G, Punta G, Juvonen T, Alfieri O, Gabbieri D, Mangino D, Agostinelli A, Livi U, Di Gregorio O, Minati A, Rinaldi M, Gerosa G, Faggian The Record Ita Investigators G Abstract BACKGROUND: The study aim was to compare the outcome of transapical transcatheter aortic valve replacement (TaTAVR) and traditional aortic valve replacement (AVR) in red...
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
In conclusion, subanalyses of DOAC landmark AF trials revealed that dabigatran, rivaroxaban, and apixaban may be safely used in AF patients with certain types of VHD: aortic stenosis, aortic regurgitation, and mitral regurgitation. More evidence is needed before routinely recommending these agents for patients with bioprosthetic valves or mild mitral stenosis. Patients with moderate to severe mitral stenosis or mechanical valves should continue to receive warfarin, as these patients were excluded from all landmark AF trials.
Source: Clinical Cardiology - Category: Cardiology Authors: Tags: Reviews Source Type: research
Authors: Montarello NJ, Nelson AJ, Sidharta SL, Worthley SG Abstract Transcatheter aortic valve implantation (TAVI) can now be considered a standard of care for inoperable and high-risk surgical patients with severe aortic stenosis, and its uptake worldwide is rapidly increasing. Indeed, many centers performing the procedure have now moved towards treating intermediate-risk patients with TAVI rather than referring them for surgical aortic valve replacement. Although the incidence of peri-procedural acute and subacute stroke following TAVI has fallen to 2-5%, its occurrence can be life-threatening and life-changing,...
Source: Journal of Heart Valve Disease - Category: Cardiology Tags: J Heart Valve Dis Source Type: research
More News: Academia | Bleeding | Cardiology | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Stroke | Study | Women